Safety of Amiodarone and Ranolazine Together in Patients With Angina
Status:
Unknown status
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Ranolazine is an effective and remarkably safe agent for the treatment of patients with
chronic stable angina, but its inhibition of voltage gated potassium channels and
electrocardiogram (EKG) corrected QT (QTc) prolongation properties have lead many to question
its safety when combined with antiarrhythmic drugs. The investigators have proposed a study
to determine the safety of ranolazine in patients with chronic stable angina who also take
amiodarone. And are conducting a prospective single-center randomized single-blinded placebo
controlled trial to run out of our large cardiology practice setting at Cardiovascular
Consultants of Nevada. The hypothesis is that there will be no difference in the ventricular
arrhythmia burden. The primary outcome will be the measurement of ventricular arrhythmia
episodes on serial holter monitor and other serially acquired recordings (such as
electrocardiogram, pacemaker or implantable defibrillator (ICD) data, and stress test data)
over a three month trial period.